Partial
Partially Aligned
Patient Risk:
Low
Summary
Some claims (drug class and hypertension indication) are supported by the label excerpts, but multiple other claims are unsupported by the provided prescribing information (FDA first approval year and patent-related claims). Angina treatment is not supported as an indication; the label describes angina exacerbation/induction risk with injection in certain patients.
Category Scores
Accurate Statements
Nicardipine is a calcium channel blocker.
Supported by Section 12.1 (Mechanism of Action): 'Nicardipine inhibits the transmembrane influx of calcium ions...'.
Nicardipine has been used to treat hypertension.
Supported by Section 1.1 (Hypertension indication) and Section 14 (Effects in Hypertension).
Unsupported Statements
Nicardipine was first approved by the FDA in 1985 for the treatment of hypertension.
FDA approval year/date is not provided in the supplied label excerpts.
Nicardipine has a total of 24 granted patents in the United States alone.
Patent counts are not provided in the supplied prescribing information excerpts.
Pharmaceutical companies are seeking new patents for nicardipine.
Patent activity is not provided in the supplied prescribing information excerpts.
Several companies have filed patent applications for new formulations and uses of nicardipine.
Patent filing activity is not provided in the supplied prescribing information excerpts.
A patent application filed by Pfizer in 2020 describes a novel formulation of nicardipine designed to improve bioavailability.
Specific patent details are not provided in the supplied prescribing information excerpts.
A patent application filed by Pfizer in 2020 describes a novel formulation of nicardipine designed to reduce side effects.
Specific patent details are not provided in the supplied prescribing information excerpts.
A patent application filed by Merck in 2019 describes a method of using nicardipine to treat atherosclerosis.
Specific patent details and any labeled indication for atherosclerosis are not provided in the supplied prescribing information excerpts.
Contradictions
Low
AI Statement
Nicardipine has been used to treat angina.
Label Reference
Section 5.1 and Section 6.1: the label describes increases/exacerbation or induction of angina (not a labeled treatment indication).
Important Omissions
None identified that are material to safely and accurately evaluate the specific claims made (the main issues are unsupported patent/approval-year claims and an angina 'treatment' framing that conflicts with the label's angina-exacerbation wording).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most unsupported claims are about patents/approval history, which are not directly prescribing or dosing-safety assertions. The angina-related statement is framed as treatment, whereas the label discusses angina induction/exacerbation risk, making that claim directionally misleading relative to label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Angina claim is inconsistent with label wording (label describes exacerbation/induction of angina rather than treatment indication). Multiple patent/approval-year claims are unsupported by the provided prescribing information.
Suggested Improvement
Limit statements to label-supported facts from Sections 1.1, 12.1, and 14; remove or clearly separate patent/approval-year claims from label-based evaluation, and rephrase angina-related content to reflect 'exacerbation/induction' as described in Sections 5.1 and 6.1.